NASDAQ:PASG Passage Bio - PASG Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.53 0.00 (0.00%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.30▼$1.5450-Day Range$1.06▼$1.8852-Week Range$1.04▼$5.33Volume270,153 shsAverage Volume170,356 shsMarket Capitalization$83.47 millionP/E RatioN/ADividend YieldN/APrice Target$11.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Passage Bio MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside640.7% Upside$11.33 Price TargetShort InterestHealthy1.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.89Based on 4 Articles This WeekInsider TradingSelling Shares$10,898 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.49) to ($1.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.05 out of 5 starsMedical Sector10th out of 1,055 stocksBiological Products, Except Diagnostic Industry3rd out of 170 stocks 4.4 Analyst's Opinion Consensus RatingPassage Bio has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.33, Passage Bio has a forecasted upside of 640.7% from its current price of $1.53.Amount of Analyst CoveragePassage Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.17% of the float of Passage Bio has been sold short.Short Interest Ratio / Days to CoverPassage Bio has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Passage Bio has recently decreased by 7.97%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPassage Bio does not currently pay a dividend.Dividend GrowthPassage Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PASG. Previous Next 3.3 News and Social Media Coverage News SentimentPassage Bio has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Passage Bio this week, compared to 1 article on an average week.Search Interest7 people have searched for PASG on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Passage Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Passage Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,898.00 in company stock.Percentage Held by Insiders14.10% of the stock of Passage Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.99% of the stock of Passage Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Passage Bio are expected to grow in the coming year, from ($2.49) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Passage Bio is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Passage Bio is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPassage Bio has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Passage Bio (NASDAQ:PASG) StockPassage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More Receive PASG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address PASG Stock News HeadlinesJanuary 27, 2023 | americanbankingnews.comBrokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $11.33January 24, 2023 | msn.com‘Passages’ Sundance Film Review: Ira Sachs’ Polyamorous Drama Excites & FrustratesJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 20, 2023 | finance.yahoo.comPassage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 7, 2023 | finance.yahoo.comAfter losing 67% in the past year, Passage Bio, Inc. (NASDAQ:PASG) institutional owners must be relieved by the recent gainDecember 15, 2022 | markets.businessinsider.comExpert Ratings for Passage BioDecember 14, 2022 | finance.yahoo.comPassage Bio Stock Jumps After Gene Therapy Study In Lysosomal Storage DisorderDecember 14, 2022 | msn.comPassage Bio posts early Phase 1/2 data for lysosomal storage disease drugJanuary 27, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 14, 2022 | markets.businessinsider.comPassage Bio Says New Interim Data From Imagine-1 Clinical Study Strengthens Safety Profile Of PBGM01December 14, 2022 | finance.yahoo.comPassage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 StudyNovember 21, 2022 | finance.yahoo.comEstimating The Fair Value Of Passage Bio, Inc. (NASDAQ:PASG)November 10, 2022 | bizjournals.comPhiladelphia gene therapy developer Passage Bio trims workforce by another 23%November 10, 2022 | finance.yahoo.comPassage Bio Reports Third Quarter 2022 Financial Results and Provides Business UpdatesNovember 8, 2022 | finance.yahoo.comPassage Bio to Present at Guggenheim 4th Annual Immunology & Neurology DayNovember 3, 2022 | finance.yahoo.comPassage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022October 11, 2022 | finance.yahoo.comHere's Why Passage Bio (NASDAQ:PASG) Must Use Its Cash WiselyOctober 10, 2022 | bizjournals.comPhiladelphia gene therapy developer Passage Bio names former Novartis executive as new CEOOctober 10, 2022 | nasdaq.comPassage Bio Names William Chou CEO With Immediate Effect - Quick FactsOctober 10, 2022 | marketwatch.comPassage Bio Names William Chou CEO >PASGOctober 10, 2022 | finance.yahoo.comPassage Bio Announces Appointment of William Chou, M.D. as Chief Executive OfficerSeptember 26, 2022 | finance.yahoo.comPassage Bio to Present at Chardan’s 6th Annual Genetic Medicines ConferenceSeptember 7, 2022 | benzinga.comNewman Ferrara LLP Announces Corporate Governance Investigations of Passage Bio, Inc. (PASG)August 11, 2022 | msn.comPassage Bio Commences Initial-Stage Brain Disorder StudyAugust 5, 2022 | finance.yahoo.comPassage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual ConferenceAugust 4, 2022 | msn.comPassage Bio: Q2 Earnings InsightsAugust 4, 2022 | finance.yahoo.comPassage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business HighlightsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PASG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address PASG Company Calendar Last Earnings11/10/2022Today1/27/2023Next Earnings (Estimated)3/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PASG CUSIPN/A CIK1787297 Webwww.passagebio.com Phone267-866-0311FaxN/AEmployees133Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.33 High Stock Price Forecast$24.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+640.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-185,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.38% Return on Assets-50.63% Debt Debt-to-Equity RatioN/A Current Ratio10.29 Quick Ratio10.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.89 per share Price / Book0.26Miscellaneous Outstanding Shares54,553,000Free Float46,861,000Market Cap$83.47 million OptionableNot Optionable Beta0.99 Key ExecutivesDr. William Chou M.D.CEO & DirectorDr. James M. Wilson M.D. (Age 67)Ph.D., Co-Founder & Chief Scientific Advisor Ms. Simona King (Age 50)CFO & Corp. Sec. Mr. Alexandros Fotopoulos MBA (Age 53)MSc, Chief Technical Officer Comp: $400.11kMr. Stuart M. HendersonVP of Corp. Devel. & Investor RelationsMr. Edgar B. Cale Esq. (Age 58)J.D., Gen. Counsel & Company Sec. Gregory FuestVP of Global Commercial Strategy & MarketingDr. Mark Forman M.D. (Age 58)Ph.D., Chief Medical Officer Desiree Luthman D.D.S.Sr. VP of Global Regulatory AffairsDavid Weinstein M.D.Sr. VP of Clinical Devel.More ExecutivesKey CompetitorsAligos TherapeuticsNASDAQ:ALGSSenti BiosciencesNASDAQ:SNTIProtalix BioTherapeuticsNYSE:PLXCidara TherapeuticsNASDAQ:CDTXAmbrx BiopharmaNYSE:AMAMView All CompetitorsInsiders & InstitutionsMarquette Asset Management LLCBought 67,101 shares on 1/12/2023Ownership: 0.123%Sandip KapadiaSold 5,000 sharesTotal: $5,950.00 ($1.19/share)Alexandros FotopoulosSold 3,720 sharesTotal: $4,947.60 ($1.33/share)Vanguard Group Inc.Bought 173,537 shares on 11/15/2022Ownership: 3.697%BlackRock Inc.Sold 24,405 shares on 11/15/2022Ownership: 2.464%View All Insider TransactionsView All Institutional Transactions PASG Stock - Frequently Asked Questions Should I buy or sell Passage Bio stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PASG shares. View PASG analyst ratings or view top-rated stocks. What is Passage Bio's stock price forecast for 2023? 8 brokers have issued 1-year price targets for Passage Bio's shares. Their PASG share price forecasts range from $5.00 to $24.00. On average, they expect the company's stock price to reach $11.33 in the next twelve months. This suggests a possible upside of 640.7% from the stock's current price. View analysts price targets for PASG or view top-rated stocks among Wall Street analysts. How have PASG shares performed in 2023? Passage Bio's stock was trading at $1.38 at the beginning of 2023. Since then, PASG stock has increased by 10.9% and is now trading at $1.53. View the best growth stocks for 2023 here. When is Passage Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023. View our PASG earnings forecast. How were Passage Bio's earnings last quarter? Passage Bio, Inc. (NASDAQ:PASG) announced its earnings results on Thursday, November, 10th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.26. What other stocks do shareholders of Passage Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include Alector (ALEC), NVIDIA (NVDA), Advanced Micro Devices (AMD), DocuSign (DOCU), Intel (INTC), Alteryx (AYX), Gossamer Bio (GOSS), JD.com (JD), Micron Technology (MU) and Black Diamond Therapeutics (BDTX). When did Passage Bio IPO? (PASG) raised $126 million in an initial public offering (IPO) on Friday, February 28th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Chardan was co-manager. What is Passage Bio's stock symbol? Passage Bio trades on the NASDAQ under the ticker symbol "PASG." Who are Passage Bio's major shareholders? Passage Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Marquette Asset Management LLC (0.12%). Insiders that own company stock include Alexandros Fotopoulos, Athena Countouriotis, Bruce A Goldsmith, Gary Romano, Jill M Quigley, Life Sciences Ix LP Frazier, Orbimed Advisors Llc, Richard Steven Morris, Sandip Kapadia and Thomas Woiwode. View institutional ownership trends. How do I buy shares of Passage Bio? Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Passage Bio's stock price today? One share of PASG stock can currently be purchased for approximately $1.53. How much money does Passage Bio make? Passage Bio (NASDAQ:PASG) has a market capitalization of $83.47 million. The company earns $-185,390,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis. How many employees does Passage Bio have? The company employs 133 workers across the globe. How can I contact Passage Bio? Passage Bio's mailing address is TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103. The official website for the company is www.passagebio.com. The company can be reached via phone at 267-866-0311 or via email at investors@passagebio.com. This page (NASDAQ:PASG) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.